TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23611305

Group type: EXPERIMENTAL
Intervention: Older cousin with drug abuse (DA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cousin pairs with closer age differences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cousin pairs growing up in high geographical proximity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male-male cousin pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older → younger cousin transmission
Number of subjects: 0
Study: 22136751

Group type: COMPARATOR
Intervention: Menaquinone-4 (MK-4) 45 mg
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (various doses)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Vitamin K status (general)
Number of subjects: 450
Study: 20369616

Group type: EXPERIMENTAL
Intervention: Remaxol infusion solution
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 17578978

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg before surgery and 200 mg every 12 h for 14 days postoperatively
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo before surgery and matching placebo for 14 days postoperatively
Number of subjects: 200
Study: 15589464

Group type: COMPARATOR
Intervention: Fenoldopam infusion at 0.025 microg/kg/min titrated to 0.1 microg/kg/min for 48 hours post-op
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antibody induction (AI) using antithymocyte globulin (AT-G(r))
Number of subjects: 20
Study: 12110157

Group type: EXPERIMENTAL
Intervention: Diagnostic and treatment algorithms to optimize antibiotic use in nursing homes
Number of subjects: 0
Study: 10099862

Group type: EXPERIMENTAL
Intervention: Lamotrigine (100 mg/day)
Number of subjects: 24
Study: 2157313

Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg plus Furosemide 40 mg
Number of subjects: 10
Study: 446302

Group type: EXPERIMENTAL
Intervention: Surgical removal of pulmonary metastases
Number of subjects: 67

Group type: COMPARATOR
Intervention: No surgical intervention
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Wedge excision
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pneumonectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: First filter of haematogenous metastases in the lung
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: First filter of haematogenous metastases in the liver
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Prolonged interval before recurrence
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Short interval before recurrence
Number of subjects: 67
Study: 31885341

Group type: EXPERIMENTAL
Intervention: Gradual oculomotor training (GOT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-intensity trainings
Number of subjects: 120
Study: 30702960

Group type: COMPARATOR
Intervention: Traditional Outline (OUT)
Number of subjects: 31
Study: 29513111

Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte adsorptive apheresis (GMA)
Number of subjects: 95
Study: 27003645

Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 127
Study: 24998014

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 328

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 328
Study: 21556746

Group type: EXPERIMENTAL
Intervention: i.m. vitamin D (300,000 IU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: i.m. placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: p.o. vitamin D (300,000 IU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: p.o. placebo
Number of subjects: 120
Study: 20566359

Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate 5mg/day for 14 days (group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Folic acid 4mg/day for 14 days (group B)
Number of subjects: 86
Study: 17447826

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specifically olanzapine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 16251617

Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified fish sauce (9 mmol (500 mg) Fe/L) for 18 months
Number of subjects: 576

Group type: COMPARATOR
Intervention: Unfortified fish sauce (Control Group)
Number of subjects: 576
Study: 14601477

Group type: EXPERIMENTAL
Intervention: Resistance to activated protein C (APC-R)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Protein S activity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Activated protein C resistance (APC-R)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Leiden mutation detection by PCR
Number of subjects: 29
Study: 10954888

Group type: EXPERIMENTAL
Intervention: Potent combination antiretroviral therapy
Number of subjects: 10
Study: 9004781

Group type: EXPERIMENTAL
Intervention: Zinc Acexamate (600 mg/d)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Famotidine (40 mg/d)
Number of subjects: 199
Study: 1284003

Group type: COMPARATOR
Intervention: Transurethral incision of the prostate (TUI, n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral prostatectomy (TURP, n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both operations (TURP and TUI)
Number of subjects: 60
Study: 6398312

Group type: EXPERIMENTAL
Intervention: Thymopentin administered subcutaneously (s.c.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymopentin administered intravenously (i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymopentin (both routes)
Number of subjects: 0
Study: 29863444

Group type: EXPERIMENTAL
Intervention: Ingroup condition including gay and lesbian individuals
Number of subjects: 90

Group type: COMPARATOR
Intervention: Outgroup condition including gay and lesbian individuals
Number of subjects: 90
Study: 29932784

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Internet-based mindfulness-based cognitive therapy (eMBCT)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: eMBCT
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both interventions (MBCT and eMBCT)
Number of subjects: 245
Study: 27503351

Group type: EXPERIMENTAL
Intervention: PCV13 reduced schedule (2 and 4 months)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PCV13 accelerated schedule (2, 3, and 4 months)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PCV13 extended schedule (2, 4, and 6 months)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: All schedules (reduced, accelerated, extended)
Number of subjects: 210
Study: 24994476

Group type: EXPERIMENTAL
Intervention: Lithium treatment (n = 8)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo treatment (n = 11)
Number of subjects: 19
Study: 21964618

Group type: EXPERIMENTAL
Intervention: Misoprostol rinse
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 48
Study: 20686486

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 4004

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 4004

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 4004
Study: 18939907

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4728

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 4728
Study: 16164506

Group type: EXPERIMENTAL
Intervention: Transitional discharge model (TDM) of care with peer support for 1 year and ongoing support from hospital staff
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Transitional discharge model (TDM) of care
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study: 14515443

Group type: EXPERIMENTAL
Intervention: ALL-BFM 90 protocol chemotherapy for 2 years
Number of subjects: 352

Group type: COMPARATOR
Intervention: Previous study ALL-BFM 83 protocol
Number of subjects: 352
Study: 10795953

Group type: EXPERIMENTAL
Intervention: Self-discrepancy magnitude and salience condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 8879341

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Bisoprolol (2.5 to 10 mg)/Hydrochlorothiazide (HCTZ) 6.25
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 218
Study: 1299488

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30938233

Group type: EXPERIMENTAL
Intervention: Women's experience with battering scale (WEB-scale)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors
Number of subjects: 882
Study: 31245907

Group type: EXPERIMENTAL
Intervention: Iguratimod plus corticosteroid (diprospan, intramuscular injection, 25 mg, twice daily for 24 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Iguratimod plus corticosteroid
Number of subjects: 30
Study: 28912447

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting survival based on seven independent prognostic factors (age, tumor stage, tumor size, ALT, ALB, CA 19-9, HBV infection status)
Number of subjects: 1526
Study: 25627452

Group type: EXPERIMENTAL
Intervention: Compression socks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23599170

Group type: EXPERIMENTAL
Intervention: Combined rehabilitation intervention (12 weeks of exercise training and 1 year of psycho-educational follow-up)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 196
Study: 22409849

Group type: EXPERIMENTAL
Intervention: Cryoablation treatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study: 19123148

Group type: EXPERIMENTAL
Intervention: Two-site phacotrabeculectomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: MICS + trabeculectomy
Number of subjects: 58
Study: 17699388

Group type: EXPERIMENTAL
Intervention: Low-dosage enoxaparin
Number of subjects: 10

Group type: COMPARATOR
Intervention: AngII infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 10
Study: 15507176

Group type: EXPERIMENTAL
Intervention: Trastuzumab added to chemotherapy
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Trastuzumab added to anthracycline (doxorubicin or epirubicin) plus cyclophosphamide (AC)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Trastuzumab added to paclitaxel
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Trastuzumab added to AC
Number of subjects: 469
Study: 11593955

Group type: EXPERIMENTAL
Intervention: Eye Movement
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Visual Noise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Exposure Alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline to Post exposure
Number of subjects: 18
Study: 9610080

Group type: EXPERIMENTAL
Intervention: Diabetics with CHD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diabetics without CHD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diabetics with CHD vs Diabetics without CHD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: NIDDM vs IDDM
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 8072077

Group type: EXPERIMENTAL
Intervention: Oral methyltestosterone (2 different commercial preparations) for 1 month
Number of subjects: 22
Study: 3292630

Group type: EXPERIMENTAL
Intervention: Prophylactic lidocaine strategy
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Selective lidocaine strategy
Number of subjects: 333
Study: 31402742

Group type: EXPERIMENTAL
Intervention: Inverse prism (IP) therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional prism (CP) therapy
Number of subjects: 100
Study: 28002679

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg every 24 weeks)
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Interferon beta-1a (44 μg three times weekly)
Number of subjects: 1656
Study: 25887660

Group type: EXPERIMENTAL
Intervention: Timed-Up-and-Go Test (TUG)
Number of subjects: 259
Study: 23687227

Group type: EXPERIMENTAL
Intervention: GlideScope® video laryngoscope (GVLs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Direct laryngoscope (DL)
Number of subjects: 23
Study: 21355718

Group type: EXPERIMENTAL
Intervention: Intradermal microneedle delivery of insulin lispro (IL)
Number of subjects: 10
Study: 18536954

Group type: EXPERIMENTAL
Intervention: Cinacalcet (15 then 30 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16890577

Group type: EXPERIMENTAL
Intervention: Lopinavir (400 mg twice daily)/ritonavir (100 mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg twice daily (after dose adjustment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lamotrigine 50 mg once daily on days 1 and 2 and 100 mg twice daily on day 3 through day 10
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lamotrigine 2N‐glucuronide to lamotrigine
Number of subjects: 24
Study: 15612851

Group type: EXPERIMENTAL
Intervention: clinical workshop only
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: workshop plus practice feedback
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: workshop plus individual coaching sessions
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: workshop, feedback, and coaching
Number of subjects: 140

Group type: COMPARATOR
Intervention: waiting list control group of self‐guided training
Number of subjects: 140
Study: 11359886

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine dressing
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Amorphous hydrogel dressing (Intrasite Gel)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control dressing (paraffin gauze)
Number of subjects: 42
Study: 8988823

Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 121

Group type: COMPARATOR
Intervention: Relaxing suggestions
Number of subjects: 121

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 121

Group type: COMPARATOR
Intervention: Operating room noise
Number of subjects: 121
Study: 8267175

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 ng/mL
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Alfentanil 28.8 ng/mL
Number of subjects: 79

Group type: COMPARATOR
Intervention: No opioid (control)
Number of subjects: 79
Study: 3311051

Group type: EXPERIMENTAL
Intervention: Triamcinolone subacromial bursa injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Naproxen therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31892574

Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Single-dose RSB analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RSB analgesia in cancer patients
Number of subjects: 56
Study: 30470591

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing regimens
Number of subjects: 3223

Group type: EXPERIMENTAL
Intervention: Panitumumab-containing regimens
Number of subjects: 3223
Study: 27398889

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine for 72 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for 72 hours
Number of subjects: 48
Study: 25736126

Group type: EXPERIMENTAL
Intervention: DEX 0.3 micro;g/kg followed by propofol 1 mg/kg (group D)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol 2 mg/kg (group C)
Number of subjects: 90
Study: 23263721

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 70
Study: 20411230

Group type: EXPERIMENTAL
Intervention: Anterior minimally invasive (MIS) approach
Number of subjects: 109

Group type: COMPARATOR
Intervention: Regular transgluteal (TG) approach
Number of subjects: 109
Study: 19906340

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-15 mg/d)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (in risperidone subgroup)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo (in risperidone subgroup)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (in quetiapine subgroup)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo (in quetiapine subgroup)
Number of subjects: 323
Study: 17692117

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion (0.05 units/kg/h)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard neonatal care
Number of subjects: 500
Study: 15893156

Group type: EXPERIMENTAL
Intervention: Early onset inhalant use (initiated before age 14)
Number of subjects: 2311

Group type: COMPARATOR
Intervention: No inhalant use (control group)
Number of subjects: 2311
Study: 12487852

Group type: EXPERIMENTAL
Intervention: (186)Re-lipiodol (RL) administered at doses ranging from 1 110 MBq to 2 220 MBq per patient depending on tumor volume.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (186)Re-lipiodol (RL)
Number of subjects: 0
Study: 9793223

Group type: EXPERIMENTAL
Intervention: TF index
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: modified DDE index
Number of subjects: 325
Study: 7636556

Group type: EXPERIMENTAL
Intervention: Single 20-mg IV dose of dexamethasone plus single 32-mg IV dose of ondansetron
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Single 20-mg IV dose of dexamethasone plus single 24-mg IV dose of ondansetron
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Single 20-mg IV dose of dexamethasone plus single 8-mg IV dose of ondansetron
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Adverse events across all groups
Number of subjects: 146
Study: 2236435

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/Kg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (lactose b.i.d.)
Number of subjects: 0
Study: 27093

Group type: EXPERIMENTAL
Intervention: Rolaids (2 tablets)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Di-Gel (2 tablets)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Maalox liquid (15 ml)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Conquel (2 tablets)
Number of subjects: 32
Study: 29668990

Group type: EXPERIMENTAL
Intervention: Paricalcitol (PCT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 27784414

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Insomnia Therapy (CBT-I)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Quasi-desensitization Control (CTRL) therapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combined treatment (escitalopram, sertraline, desvenlafaxine) with either CBT-I or CTRL
Number of subjects: 104
Study: 25332091

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral nutrition group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Supported exercise paired with cognitive-behavioral approach
Number of subjects: 83

Group type: COMPARATOR
Intervention: Supported exercise paired with educational approach
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Completing at least two sessions of exercise per week
Number of subjects: 83
Study: 22785552

Group type: EXPERIMENTAL
Intervention: Iloprost (1.25-2.5 ng/kg/min)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 185
Study: 20706751

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride (NaCl) for 60 s
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 10% sodium hypochlorite (NaOCl) for 60 s
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 17% ethylenediaminetetraacetic acid (EDTA) for 60 s followed by 5.25% NaOCl for 60 s
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DUO‐LINK cement
Number of subjects: 39

Group type: COMPARATOR
Intervention: LuxaCore Dual cement
Number of subjects: 39
Study: 17875551

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 102

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 102
Study: 17051601

Group type: EXPERIMENTAL
Intervention: D2 with para-aortic lymph node dissection
Number of subjects: 523
Study: 15189638

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 0
Study: 10930484

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both imaging studies
Number of subjects: 106
Study: 9307129

Group type: EXPERIMENTAL
Intervention: Thermal stimulation using a Peltier thermode heated to 45‐53 degrees C, applied in brief (700 ms) contacts at interstimulus intervals (ISIs) of 3 s.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermal stimulation at frequencies of > or = 0.33 Hz.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior administration of dextromethorphan (a N‐methyl‐D‐aspartate receptor antagonist).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternating stimulation of adjacent but nonoverlapping skin sites at 0.33 Hz.
Number of subjects: 0
Study: 8458045

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (0.25, 0.5, 1, or 2 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 2942426

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with local anesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laparoscopy under general anesthesia
Number of subjects: 120
Study: 28358570

Group type: EXPERIMENTAL
Intervention: Lunchtime park walks
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 97